Gold Prices Steady as Hormuz Tensions Fuel Fed Rate Concerns 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Gold Price Hits Seven-Week High as Fed Rate Hike Bets Fade and Hormuz Deal Hopes Grow 
Asian Currencies Steady as Markets Await U.S. Jobs Data 
Asian Stocks Mixed as Chip Selloff Hits KOSPI, Nikkei Ahead of US Jobs Data 
US Stock Futures Flat as Iran Strait of Hormuz Demands Fuel Oil Concerns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
US Stock Futures Rise as Markets Await July Payrolls Data 
Oil Prices Set for Steep Weekly Losses as Hormuz Deal Stalls 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
